Adicet Bio to Present at J.P. Morgan Healthcare Conference

MENLO PARK, Calif., Jan. 9, 2020 /PRNewswire/ -- Adicet Bio, Inc.  a biopharmaceutical company focused on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells, announced today that the company will present at the 38th Annual J.P. Morgan Healthcare Conference. 

Anil Singhal, Ph.D., President and Chief Executive Officer of Adicet Bio, will provide a company overview on Thursday, January 16, 2020, at 7:30am PT.

About Adicet Bio, Inc.
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors. Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs are being used to arm T cells or as T cell engagers in solid tumors. In August 2016, Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.

For more information, please visit our website at http://www.adicetbio.com.

Contact: 
Anne Bowdidge
Investor Relations
650-218-6900
ir@adicetbio.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/adicet-bio-to-present-at-jp-morgan-healthcare-conference-300983993.html

SOURCE Adicet Bio, Inc.